Bharat [BIBCL] vs Panacea Biotec [PANACEABIO] Detailed Stock Comparison

Bharat Immunologicals & Biologicals Corporation Limited

BSE
Loading...

Panacea Biotec Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Bharat Immunologicals & Biologicals Corporation Limited wins in 4 metrics, Panacea Biotec Ltd. wins in 13 metrics, with 0 ties. Panacea Biotec Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bharat Immunologicals & Biologicals Corporation Limited Panacea Biotec Ltd. Better
P/E Ratio (TTM) -4.59 182.62 Panacea Biotec Ltd.
Price-to-Book Ratio 0.97 2.65 Bharat Immunologicals & Biologicals Corporation Limited
Debt-to-Equity Ratio 94.48 2.79 Panacea Biotec Ltd.
PEG Ratio -0.08 -15.02 Bharat Immunologicals & Biologicals Corporation Limited
EV/EBITDA -7.13 -65.87 Bharat Immunologicals & Biologicals Corporation Limited
Profit Margin (TTM) -241.59% -1.29% Panacea Biotec Ltd.
Operating Margin (TTM) -2,888.44% 1.99% Panacea Biotec Ltd.
EBITDA Margin (TTM) N/A 1.99% N/A
Return on Equity -21.00% -1.01% Panacea Biotec Ltd.
Return on Assets (TTM) -6.28% -0.65% Panacea Biotec Ltd.
Free Cash Flow (TTM) $108.92M $-776.74M Bharat Immunologicals & Biologicals Corporation Limited
1-Year Return -32.86% 18.85% Panacea Biotec Ltd.
Price-to-Sales Ratio (TTM) 9.97 3.61 Panacea Biotec Ltd.
Enterprise Value $1.42B $19.26B Panacea Biotec Ltd.
EV/Revenue Ratio 18.52 3.18 Panacea Biotec Ltd.
Gross Profit Margin (TTM) N/A 58.88% N/A
Revenue per Share (TTM) $2 $99 Panacea Biotec Ltd.
Earnings per Share (Diluted) $-3.59 $-1.28 Panacea Biotec Ltd.
Beta (Stock Volatility) 0.34 0.14 Panacea Biotec Ltd.

Bharat Immunologicals & Biologicals Corporation Limited vs Panacea Biotec Ltd. Stock Performance Analysis

Loading Price Chart...

BIBCL
PANACEABIO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bharat Immunologicals & Biologicals Corporation Limited0.71%-1.61%-1.38%5.28%-9.50%-14.68%
Panacea Biotec Ltd.0.90%-2.19%39.94%70.71%51.42%43.20%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bharat Immunologicals & Biologicals Corporation Limited-32.86%-26.70%-80.09%-12.27%29.14%57.16%
Panacea Biotec Ltd.18.85%307.76%44.67%440.21%276.43%141.23%

Performance & Financial Health Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs Panacea Biotec Ltd.

MetricBIBCLPANACEABIO
Market Information
Market Cap i₹762.99M₹21.84B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i35,100168,211
90 Day Avg. Volume i35,515144,184
Last Close₹17.14₹540.80
52 Week Range₹14.10 - ₹25.65₹292.40 - ₹647.00
% from 52W High-33.18%-16.41%
All-Time High₹94.50 (Jun 14, 2021)₹647.00 (Jun 09, 2026)
% from All-Time High-81.86%-16.41%
Growth Metrics
Quarterly Revenue Growth-0.99%0.01%
Quarterly Earnings Growth-1.00%-0.12%
Financial Health
Profit Margin (TTM) i-2.42%-0.01%
Operating Margin (TTM) i-28.88%0.02%
Return on Equity (TTM) i-0.21%-0.01%
Debt to Equity (MRQ) i94.482.79
Cash & Liquidity
Book Value per Share (MRQ)₹18.24₹134.77
Cash per Share (MRQ)₹2.07₹13.86
Operating Cash Flow (TTM) i₹87.48M₹-1,511,860,000
Levered Free Cash Flow (TTM) i₹-166,388,000₹-83,700,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A₹0.00

Valuation & Enterprise Metrics Analysis: Bharat Immunologicals & Biologicals Corporation Limited vs Panacea Biotec Ltd.

MetricBIBCL (Apr 26, 2026)PANACEABIO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-4.59182.62
Forward P/E iN/AN/A
PEG Ratio i-0.08-15.02
Price to Sales (TTM) i9.973.61
Price to Book (MRQ) i0.972.65
Market Capitalization
Market Capitalization i₹762.99M₹21.84B
Enterprise Value i₹1.42B₹19.26B
Enterprise Value Metrics
Enterprise to Revenue i18.523.18
Enterprise to EBITDA i-7.13-65.87
Risk & Other Metrics
Beta i0.340.14
Book Value per Share (MRQ) i₹18.24₹134.77

Financial Statements Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs Panacea Biotec Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIBCL (2023)PANACEABIO (2025)
Revenue/Sales i446.09M4.93B
Cost of Goods Sold i422.08M2.36B
COGS % of Revenue i94.6%47.9%
Gross Profit i24.01M2.57B
Gross Margin i5.4%52.1%
Research & Development i0N/A
Operating Income (EBIT) i-160.07M-556.12M
Operating Margin i-35.9%-11.3%
EBITDA i-154.93M-76.28M
EBITDA Margin i-34.7%-1.5%
Pre-Tax Income i-222.68M-79.48M
Pre-Tax Income % of Revenue i-49.9%-1.6%
Income Tax i-56.29M7.71M
Income Tax % of Revenue i-12.6%0.2%
Net Income (Profit) i-166.39M-87.19M
Profit Margin i-37.3%-1.8%

Balance Sheet & Liquidity Metrics

MetricBIBCL (2023)PANACEABIO (2025)
Cash & Equivalents i12.86M821.25M
Total Current Assets i358.03M5.45B
Total Current Assets % of Revenue i80.3%110.7%
Total Current Liabilities i940.42M3.67B
Total Current Liabilities % of Revenue i210.8%74.5%
Long-Term Debt iN/A150.00M
Long-Term Debt % of Revenue i0.0%3.0%
Total Shareholders Equity i882.14M8.31B
Retained Earnings i-662.11M7.80B
Retained Earnings % of Revenue i-148.4%158.3%
Property, Plant & Equipment i72.02M5.43B

Cash Flow Statement Comparison

MetricBIBCL (2023)PANACEABIO (2025)
Operating Cash Flow i87.48M-1.51B
Operating Cash Flow % of Revenue i19.6%-30.7%
Capital Expenditures i0-497.30M
Free Cash Flow i108.92M-776.74M
FCF Margin i24.4%-15.8%
Debt Repayment iN/A0
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBIBCLPANACEABIO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i43.18M61.25M
Float Shares i17.58M15.42M
% Held by Insiders i59.25%72.65%
% Held by Institutions i0.00%0.13%
% Held by Public i40.75%27.22%

Dividend Analysis & Yield Comparison: Bharat Immunologicals & Biologicals Corporation Limited vs Panacea Biotec Ltd.

MetricBIBCLPANACEABIO
Last 12-Month Dividend iN/A₹0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A₹0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A₹0.00
Ex-Dividend DateN/AN/A